Pharmaceutical industry developments : specialty drugs, coupons, reverse payments and product hopping / Kristy Bishop, editor.

Format:

Book

Contributor:

Bishop, Kristy, editor.

Series:

Pharmacology-research, safety testing, and regulation series.

Pharmacology - Research, Safety Testing and Regulation

Language:

English

Subjects (All):

Drugs--Prices--United States.

Drugs.

Physical Description:

1 online resource (139 p.)

Place of Publication:

New York : Nova Publishers, 2016.

Summary:

Specialty drugs are one of the fastest-growing areas of health care spending. There is no one set definition of specialty drugs, although insurers and other health care payers often characterize them as prescription products requiring extra handling or administration that are used to treat complex diseases including hepatitis C, multiple sclerosis, and cancer. High cost can trigger a specialty drug designation. Biologics, or drugs derived from living cells, are often but not always deemed to be specialty drugs. This book provides background on specialty drugs. To put specialty drug development, distribution, and spending in context, the book provides information about broader U.S. prescription drug pricing, insurance, and regulatory trends. Furthermore, this book explains the difference between coupons and other pharmaceutical assistance and incentive programs offered by manufacturers, pharmacies, states, and nonprofit organizations; outlines federal laws and regulations and private-sector policies relating to coupons and other financial incentives for consumers/patients to purchase prescription drugs; and introduces and analyzes innovation and competition policy issues associated with the pharmaceutical industry.

Contents:

PHARMACEUTICAL INDUSTRY DEVELOPMENTS: SPECIALTY DRUGS, COUPONS, REVERSE PAYMENTS AND PRODUCT HOPPING; PHARMACEUTICAL INDUSTRY DEVELOPMENTS: SPECIALTY DRUGS, COUPONS, REVERSE PAYMENTS AND PRODUCT HOPPING; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: SPECIALTY DRUGS: BACKGROUND AND POLICY CONCERNS; INTRODUCTION; U.S. PRESCRIPTION DRUG MARKET; SPECIALTY DRUGS; SPECIALTY DRUG SPENDING TRENDS; COSTS AND BENEFITS OF SPECIALTY DRUGS; SPECIALTY DRUG SPENDING CONTROLS; OUTSTANDING ISSUES

Chapter 2: PRESCRIPTION DRUG DISCOUNT COUPONS: IMPLICATIONS FOR PUBLIC AND COMMERCIAL HEALTH CARE PLANSSUMMARY; INTRODUCTION; U.S. SPENDING FOR PRESCRIPTION DRUGS; INSURER PRESCRIPTION DRUG COST CONTROLS; MANUFACTURER CO-PAYMENT COUPONS; RESTRICTIONS ON COUPON USE; FINANCIAL IMPACT OF COUPONS; PATIENT ASSISTANCE PROGRAMS; APPENDIX A. NATIONAL EXPENDITURE DATA; APPENDIX B. FEDERAL HEALTH PROGRAMS; Chapter 3: MANUFACTURER SAFEGUARDS MAY NOT PREVENT COPAYMENT COUPON USE FOR PART D DRUGS; EXECUTIVE SUMMARY; OBJECTIVES; BACKGROUND; METHODOLOGY; FINDINGS; CONCLUSION AND RECOMMENDATION; APPENDIX A

APPENDIX BACKNOWLEDGMENTS; Chapter 4: PHARMACEUTICAL PATENT-ANTITRUST: REVERSE PAYMENT SETTLEMENTS AND PRODUCT HOPPING; SUMMARY; INTRODUCTION; THE HATCH-WAXMAN ACT; ANTITRUST FUNDAMENTALS; REVERSE PAYMENT SETTLEMENTS; PRODUCT HOPPING; ISSUES AND OBSERVATIONS; INDEX

Notes:

Includes index.

Description based on print version record.

ISBN:

1-63484-657-5